| 분자 | Cat. No. | Product Name | 종 | Host | 구조 | 순도 | Activity | 규격 및 가격 |
|---|---|---|---|---|---|---|---|---|
| HLA-A*0201 & B2M & HBV (FLLTRILTI) | Biotinylated Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | |||
| HLA-A*0201 & B2M & HBV (FLLTRILTI) | PE-Labeled Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein | Human | HEK293 | $410.00 25ug |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| GRN Gene Therapy（Eli Lilly And Company） | PR-006 | Phase 2 Clinical | Eli Lilly And Company | Frontotemporal Dementia | 상세 |
| TAK-594 | DNL-593; PTV:PGRN; TAK-594 | Phase 2 Clinical | Denali Therapeutics Inc | Frontotemporal Dementia | 상세 |
| AVB-101 | AVB-101 | Phase 2 Clinical | AviadoBio Ltd | Frontotemporal Dementia | 상세 |
| AL-101 | GSK-4527226; AL-101 | Phase 2 Clinical | Alector Inc | Nerve Degeneration; Alzheimer Disease; Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis | 상세 |
| PBFT-02 | PBFT-02 | Phase 2 Clinical | Passage Bio Inc | Frontotemporal Dementia | 상세 |
| AG-01（A&G Pharm） | AG-01（A&G Pharm） | Phase 1 Clinical | A&G Pharmaceutical | Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | 상세 |
